TYR and inflammatory bowel disease: Although neither PEA nor TYR are agonists at TAAR2, the aforementioned heterodimerization of TAAR2 with TAAR1 could provide a link between the altered TYR and PEA metabolomic profiles and TAAR2 over-expression, both of which allow discrimination of IBD populations.